Hematopoietic Cell Transplantation
Hematopoietic Cell Transplantation - Related Videos
20:38
Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)
0 Views •
Cited by 31 •
2007
08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
0 Views •
Cited by 16 •
2016
This protocol provides step-by-step guidelines for setting up competitive mouse bone marrow transplant experiments to study hematopoietic stem/progenitor cell function without prior purification of stem cells by cell sorting.
22:06
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
0 Views •
Cited by 8 •
2007
This protocol details the derivation of transplantable hematopoietic stem cells from mouse embryonic stem cells (ESC) and their subsequent injection into lethally irradiated recipient mice. Briefly, ESC are differentiated as embryoid bodies, which are then infected with retroviral HoxB4 and co-cultured with OP9 stromal cells and hematopoietic cytokines.
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
0 Views •
Cited by 2 •
2017
Quantification of donor-derived cells is required to monitor engraftment after stem cell transplantation in patients with hemoglobinopathies. A combination of flow cytometry-based cell sorting, colony formation assay, and subsequent analysis of short tandem repeats may be used to assess the proliferation and differentiation of progenitors in the erythroid compartment.
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
FAQs
Conditioning therapy suppresses the recipient’s bone marrow and immune system before cells are infused. It may use chemotherapy, radiation, or both, and prepares the recipient for the incoming hematopoietic stem and progenitor cells. This step is central to replacing impaired blood-forming activity and establishing the conditions needed for subsequent engraftment.
After infusion, hematopoietic stem and progenitor cells migrate to the bone marrow, where they engraft and begin generating new blood cells. This sequence connects the cellular transplant with restoration of blood and immune-cell production. Engraftment is therefore a key biological transition from receiving transplanted cells to rebuilding hematopoietic function.
Autologous transplantation uses the patient’s own hematopoietic cells, whereas allogeneic transplantation uses cells from a donor. The source changes the biological context of recovery because donor-derived immune cells can sometimes produce a graft-versus-leukemia effect. Thus, the two approaches differ not only in cell origin but also in the potential contribution of donor immunity.
In an allogeneic transplant, donor immune cells may contribute to a graft-versus-leukemia effect, which can help target leukemia after transplantation. However, immune activity also creates the need to manage graft-versus-host disease. These opposing considerations make donor-cell biology important when interpreting both the potential benefits and complications of treatment.
The procedure begins with conditioning using chemotherapy, radiation, or both. Hematopoietic stem and progenitor cells are then infused, whether collected from the patient or a donor. The cells migrate to the bone marrow and engraft, followed by the generation of new blood and immune cells. Clinical management continues as recovery and complications are addressed.
Hematopoietic cell transplantation is used for blood cancers, bone marrow failure, inherited blood disorders, and selected immune deficiencies. Its relevance varies with the underlying disease, but the shared therapeutic goal is to replace or restore defective blood-forming capacity. In blood cancers, donor immune activity may additionally provide a graft-versus-leukemia effect.
Infection, graft-versus-host disease, and relapse are major concerns associated with hematopoietic cell transplantation. They represent different challenges: infection reflects vulnerability during restoration of blood and immune-cell production, graft-versus-host disease involves donor immune effects, and relapse reflects return of the treated disease. Managing all three is essential to the transplant outcome.